Spyre Therapeutics enters June with an unusual combination: a stock that has drifted 6% lower on the week while the Street is broadly bullish, insider selling has been persistent, and short positions have quietly climbed to their highest level in six weeks.
Short sellers have been adding steadily. At 15.4% of the free float, short interest is up roughly a full percentage point versus a month ago, with nearly all of that build happening in a concentrated burst after early May. The ORTEX short score of 68.2 — a composite measure of squeeze and positioning risk — has been range-bound in the high 60s for two weeks, pointing to an entrenched rather than panicked bear base. Crucially, the borrow market shows no signs of stress: cost to borrow is a negligible 0.50% annually, and availability is a wide 466%, meaning shorts face no meaningful friction in adding or maintaining positions. This is not a setup primed for a squeeze.
Options positioning has shifted more cautiously over the past three weeks. The put/call ratio moved from the low 0.35 range in mid-May to 0.82 now — more than double the prior level, and modestly above its 20-day average of 0.68. That move is not yet extreme (the z-score is just 0.54), but the directional shift is notable: through May 15 the ratio tracked well below average, then reset sharply higher. Investors who were positioned for a continued rally earlier in the month are now hedging more deliberately.
The contrast with the Street's formal view is sharp. Analyst consensus is uniformly positive, with every recent coverage action a target raise — Citigroup lifted to $97, Stifel to $107, Deutsche Bank to $88, and Leerink to $106, all in April and May. The mean target of $95.20 implies roughly 38% upside from Tuesday's close of $69.16. The bull case centres on SPY001's positive Phase results in IBD and the platform's combination potential; the bear case focuses on the sequential platform trial design, small enrollment sizes, and maintenance data not expected until 2027 — a long wait for a name trading at 7x book with deeply negative earnings. The price-to-book multiple has actually compressed by around 3.5 turns over the past month, reflecting the stock's soft patch.
The insider picture adds texture. On May 1, the CEO, CFO, and Chief Medical Officer all sold shares in the same session — the CMO alone transacted nearly $2.3 million across multiple tranches. A director sold an additional $5.95 million on May 8. The 90-day net value across all insiders is solidly in selling territory at over $15.7 million. These are flagged as plan-based transactions at significance scores of 2, so they do not necessarily signal a change in conviction — but the cluster of C-suite selling near $70-75 is a data point the market has clearly absorbed.
Among correlated peers, SMMT has fallen 12.6% on the week and CYDY is down 13.8%, suggesting the broader clinical-stage IBD and biotech peer group has faced its own headwinds. RVMD is off 7.6% in the session. The next scheduled event is August 6 earnings. Prior prints have been mixed in terms of price reaction — a 4.6% and a 5.6% move higher on two occasions, and modest declines on two others. The question heading into the second half is whether the six-week short build, C-suite selling, and option-hedging pickup represent caution that is already priced in, or a market still searching for a lower entry.
See the live data behind this article on ORTEX.
Open SYRE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
